{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:12:27Z","timestamp":1790694747472,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016304","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sodium-glucose cotransporter 2 inhibitors could reduce cardiovascular events in patients with heart failure irrespective of diabetes status. In this prespecified sub-analysis of randomised-controlled trial, we investigated the efficacy of luseogliflozin (2.5\u00a0mg daily), a sodium\u2013glucose cotransporter 2 inhibitor, with that of voglibose (0.6\u00a0mg daily), an alpha-glucosidase inhibitor, on high-risk lipid profile and inflammatory markers in patients with type-2 diabetes and heart failure. Among the 157 patients studied, there were no significant differences in the mean malondialdehyde LDL or small-dense LDL cholesterol levels between the luseogliflozin and voglibose groups (percent change: 0.2% vs. \u2212\u00a00.6%, p\u2009=\u20090.93; \u2212\u00a01.7% vs. \u2212\u00a08.6%, p\u2009=\u20090.21) after 12\u00a0weeks in comparison to levels at the baseline. No significant difference was observed between the two groups in the adiponectin and high-sensitivity C-reactive protein levels after 12\u00a0weeks compared to the baseline levels (percent change, \u2212\u00a01.6% vs. \u2212\u00a04.0% and 22.5% vs. 10.0%; p\u2009=\u20090.52 and p\u2009=\u20090.55, respectively). In conclusion, in patients with type-2 diabetes and heart failure, compared to voglibose, luseogliflozin did not significantly improve the high-risk lipoprotein profile including malondialdehyde LDL and small-dense LDL cholesterol or the levels of inflammatory markers, including adiponectin and high-sensitivity C-reactive protein.<\/jats:p><jats:p><jats:bold>Trial registration:<\/jats:bold>Trial number: UMIN-CTR, UMIN000018395; Registered 23 July 2015; URL:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.umin.ac.jp\/ctr\/index.htm\">https:\/\/www.umin.ac.jp\/ctr\/index.htm<\/jats:ext-link>.<\/jats:p>","DOI":"10.1038\/s41598-022-19371-6","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T13:07:59Z","timestamp":1663160879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure"],"prefix":"10.1038","volume":"12","author":[{"given":"Kentaro","family":"Ejiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Namba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Sakuragi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Minagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Nishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Fuke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The MUSCAT-HF Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ejiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Namba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Sakuragi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Minagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Nishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Fuke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Segawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Koshiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"19371_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128 (2015).","journal-title":"N. Engl. J. Med."},{"key":"19371_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644\u2013657 (2017).","journal-title":"N. Engl. J. Med."},{"key":"19371_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347\u2013357 (2019).","journal-title":"N. Engl. J. Med."},{"key":"19371_CR4","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon, C. P. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N. Engl. J. Med. 383, 1425\u20131435 (2020).","journal-title":"N. Engl. J. Med."},{"key":"19371_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"key":"19371_CR6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"key":"19371_CR7","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink, H. J., Perkins, B. A., Fitchett, D. H., Husain, M. & Cherney, D. Z. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134, 752\u2013772 (2016).","journal-title":"Circulation"},{"key":"19371_CR8","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano, M. & Goto, S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 139, 1985\u20131987 (2019).","journal-title":"Circulation"},{"key":"19371_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1053\/j.ajkd.2016.03.410","volume":"68","author":"BA Perkins","year":"2016","unstructured":"Perkins, B. A., Udell, J. A. & Cherney, D. Z. No need to sugarcoat the message: Is cardiovascular risk reduction from SGLT2 inhibition related to natriuresis?. Am. J. Kidney Dis. 68, 349\u2013352 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"19371_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1475-2840-13-28","volume":"13","author":"DZ Cherney","year":"2014","unstructured":"Cherney, D. Z. et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc. Diabetol. 13, 28 (2014).","journal-title":"Cardiovasc. Diabetol."},{"key":"19371_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod, M. et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation 136, 249\u2013259 (2017).","journal-title":"Circulation"},{"key":"19371_CR12","doi-asserted-by":"publisher","first-page":"m3342","DOI":"10.1136\/bmj.m3342","volume":"370","author":"KB Filion","year":"2020","unstructured":"Filion, K. B. et al. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: Multi-database retrospective cohort study. BMJ 370, m3342 (2020).","journal-title":"BMJ"},{"key":"19371_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker, T. A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393, 31\u201339 (2019).","journal-title":"Lancet"},{"key":"19371_CR14","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","volume":"38","author":"D Basu","year":"2018","unstructured":"Basu, D. et al. Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition. Arterioscler. Thromb. Vasc. Biol. 38, 2207\u20132216 (2018).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"19371_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12933-016-0491-5","volume":"16","author":"T Hayashi","year":"2017","unstructured":"Hayashi, T. et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: Comparison with sitagliptin. Cardiovasc. Diabetol. 16, 8 (2017).","journal-title":"Cardiovasc. Diabetol."},{"key":"19371_CR16","doi-asserted-by":"publisher","first-page":"e026590","DOI":"10.1136\/bmjopen-2018-026590","volume":"9","author":"K Ejiri","year":"2019","unstructured":"Ejiri, K. et al. The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial. BMJ Open 9, e026590 (2019).","journal-title":"BMJ Open"},{"key":"19371_CR17","doi-asserted-by":"publisher","first-page":"e015103","DOI":"10.1161\/JAHA.119.015103","volume":"9","author":"K Ejiri","year":"2020","unstructured":"Ejiri, K. et al. Effect of luseogliflozin on heart failure with preserved ejection fraction in patients with diabetes mellitus. J. Am. Heart Assoc. 9, e015103 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"19371_CR18","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJ McMurray","year":"2012","unstructured":"McMurray, J. J. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, 1787\u20131847 (2012).","journal-title":"Eur. Heart J."},{"key":"19371_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1517\/13543784.2013.774372","volume":"22","author":"WN Washburn","year":"2013","unstructured":"Washburn, W. N. & Poucher, S. M. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin. Investig. Drugs 22, 463\u2013486 (2013).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"19371_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499\u2013502 (1972).","journal-title":"Clin. Chem."},{"key":"19371_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0005-2760(94)90100-7","volume":"1215","author":"K Kotani","year":"1994","unstructured":"Kotani, K. et al. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim. Biophys. Acta 1215, 121\u2013125 (1994).","journal-title":"Biochim. Biophys. Acta"},{"key":"19371_CR22","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1177\/030006051204000527","volume":"40","author":"K Kotani","year":"2012","unstructured":"Kotani, K., Caccavello, R., Taniguchi, N. & Gugliucci, A. Circulating soluble receptor for advanced glycation end products is inversely correlated to oxidized low-density lipoproteins in asymptomatic subjects. J. Int. Med. Res. 40, 1878\u20131883 (2012).","journal-title":"J. Int. Med. Res."},{"key":"19371_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1373\/clinchem.2010.149559","volume":"57","author":"Y Ito","year":"2011","unstructured":"Ito, Y., Fujimura, M., Ohta, M. & Hirano, T. Development of a homogeneous assay for measurement of small dense LDL cholesterol. Clin. Chem. 57, 57\u201365 (2011).","journal-title":"Clin. Chem."},{"key":"19371_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cca.2006.03.008","volume":"371","author":"A Nishimura","year":"2006","unstructured":"Nishimura, A. & Sawai, T. Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer. Clin. Chim. Acta 371, 163\u2013168 (2006).","journal-title":"Clin. Chim. Acta"},{"key":"19371_CR25","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.dsx.2019.01.016","volume":"13","author":"M Calapkulu","year":"2019","unstructured":"Calapkulu, M., Cander, S., Gul, O. O. & Ersoy, C. Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center. Diabetes Metab. Syndr. 13, 1031\u20131034 (2019).","journal-title":"Diabetes Metab. Syndr."},{"key":"19371_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12944-017-0443-4","volume":"16","author":"SA Cha","year":"2017","unstructured":"Cha, S. A. et al. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids Health Dis. 16, 58 (2017).","journal-title":"Lipids Health Dis."},{"key":"19371_CR27","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.2337\/dc12-2491","volume":"36","author":"G Schernthaner","year":"2013","unstructured":"Schernthaner, G. et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial. Diabetes Care 36, 2508\u20132515 (2013).","journal-title":"Diabetes Care"},{"issue":"Suppl 3","key":"19371_CR28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2362.1994.tb02256.x","volume":"24","author":"W Leonhardt","year":"1994","unstructured":"Leonhardt, W., Hanefeld, M., Fischer, S. & Schulze, J. Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia. Eur. J. Clin. Investig. 24(Suppl 3), 45\u201349 (1994).","journal-title":"Eur. J. Clin. Investig."},{"key":"19371_CR29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0026-0495(87)90035-7","volume":"36","author":"AD Baron","year":"1987","unstructured":"Baron, A. D., Eckel, R. H., Schmeiser, L. & Kolterman, O. G. The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics. Metabolism 36, 409\u2013415 (1987).","journal-title":"Metabolism"},{"key":"19371_CR30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0026-0495(96)90139-0","volume":"45","author":"K Shinozaki","year":"1996","unstructured":"Shinozaki, K. et al. Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism 45, 731\u2013737 (1996).","journal-title":"Metabolism"},{"key":"19371_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1161\/CIRCULATIONAHA.105.567107","volume":"113","author":"S Kathiresan","year":"2006","unstructured":"Kathiresan, S. et al. Increased small low-density lipoprotein particle number: A prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113, 20\u201329 (2006).","journal-title":"Circulation"},{"key":"19371_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2337\/diabetes.52.2.453","volume":"52","author":"WT Garvey","year":"2003","unstructured":"Garvey, W. T. et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52, 453\u2013462 (2003).","journal-title":"Diabetes"},{"key":"19371_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","volume":"85","author":"WT Garvey","year":"2018","unstructured":"Garvey, W. T. et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism 85, 32\u201337 (2018).","journal-title":"Metabolism"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19371-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19371-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19371-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T23:15:33Z","timestamp":1701040533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19371-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["19371"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-19371-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"21 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Miyoshi received a trust research\/joint research fund from Novartis Pharma K. K. Dr. Nishii is affiliated with the Endowed Department of Medtronic Japan. Dr. Ito received a trust research\/joint research fund from Novartis KK. The other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15449"}}